3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

A PROSPECTIVE STUDY TO ESTIMATE HIV INCIDENCE, RECRUITMENT AND RETENTION AMONG POTENTIAL VOLUNTEERS FOR AN HIV EFFICACY TRIAL IN RURAL UGANDA

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. WePp0206

Bwanika A.¹, Ruzagira E.¹, Nambowa R.¹, Kamali A.¹, Ketter N.², Grosskurth H.^1
1 Medical Research Council Programme on AIDS in Uganda, Entebbe, Uganda, ² International AIDS Vaccine Initiative, New york, United States of America

INTRODUCTION: To estimate the incidence of HIV infection and retention among volunteers who are at risk for HIV infection and, determine follow up rates and reason(s) for loss to follow-up to project sample sizes required for future preventive HIV vaccine trials.

METHODS: This is a 24 months observational study involving 1000 HIV negative healthy adult volunteers (18 – 60 years) enrolled from three communities that participated in a baseline HIV prevalence study (January and July 2004); the participants are followed every 3 months. Consenting volunteers are educated about the study procedures, interviewed, examined, HIV tested and provided with HIV pre- and post-test counseling at baseline and every three months. Risk factor data is also collected and volunteers are provided basic medical care and referrals for care if needed.

RESULTS: From October 2004 to February 2005, a total of 926 people have been screened, of whom, 880 (95%) have been enrolled into the study. Reasons for not being enrolled were: tested HIV positive at screening (7), awaiting HIV confirmatory test results (6) and other exclusion criteria (33). To date 471 (96%) out of 490 volunteers have completed the first 3 monthly follow up visit. Only one withdrew, 2 permanently left the study area and the remaining were temporarily absent from home (trade and visiting relatives). There were 2 incident HIV infections (~1.5%) incidence rate).

CONCLUSIONS: The high enrollment and good follow up rates, which are necessary for future HIV vaccine efficacy trials are very encouraging. This general population study contains a significant proportion of persons at risk for HIV infection.

Download PDF of this abstract.

050724
Prevention | WePp0206 | Bwanika A.
Planning For Vaccine Efficacy Trials

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.